Oncothyreon Inc., a clinical-stage biopharmaceutical company, engages in the research and development of therapeutic products for the treatment of cancer. Its clinical-stage product candidates include ONT-380, an orally active and selective small-molecule HER2 inhibitor, which is in two Phase 1b trials, one in combination with Kadcyla and another in combination with Xeloda and/or Herceptin; and ONT-10, a therapeutic vaccine in Phase 1 trial targeting the Mucin 1 peptide antigen (MUC1) for use in various cancer indications, including breast, thyroid, colon, stomach, pancreas, ovarian, and prostate, as well as certain types of lung cancer. The company is also developing Checkpoint kinase 1, a protein kinase in pre-clinical studies to inhibit tumor growth as single agents. In addition, it focuses on researching on Protocells, which are nanoparticles designed to enable the targeted delivery of various therapeutic agents, including nucleic acids, proteins, peptides, and small molecules, as well as to develop product candidates for the treatment of cancer and rare diseases. The company has a research collaboration agreement with Sentinel Oncology Ltd. for the discovery of novel Chk1 inhibitors; collaboration with Celldex Therapeutics, Inc. on a combined clinical trial of ONT-10 and varlilumab; and collaboration with Adimab LLC for the discovery of novel antibodies against undisclosed immunotherapy targets in oncology. Oncothyreon Inc. was founded in 1985 and is headquartered in Seattle, Washington.